最新ニュース Paycor HCM (NASDAQ:PYCR) 株価情報

Paycor HCM

Paycor HCM provides payroll and human capital management solutions to small and midsize clients in the United States via a software-as-a-service model. Alongside core payroll functionality, the firm's platform offers a suite of HCM solutions including talent management and time and attendance software, third-party integration capabilities, and industry-specific configurations. The firm targets customers with 10-1,000 employees and had over 30,500 customers as of June 2024.

Paycor HCM Inc

<p><strong>Barrick Gold Corporation </strong>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GOLD#NYSE">GOLD</a>) shares are trading higher Wednesday after the company reported better-than-expected <a href="https://www.benzinga.com/25/02/43657514/barrick-gold-q4-higher-realized-gold-prices-lower-aisc-but-revenue-falls-short">fourth-quarter earnings</a> and announced a new $1 billion stock buyback program.</p>
<p><strong>What To Know: </strong>The company's fourth-quarter revenue came in at $3.645 billion, up 8% from the previous quarter but missing analyst estimates of $3.978 billion. Barrick reported adjusted earnings per share of 46 cents, beating Wall Street's expectation of 41 cents. </p>
<p>CEO <strong>Mark Bristow</strong> highlighted steady operational improvements across several key projects, including Pueblo Viejo, Veladero and Nevada Gold Mines. He noted that the company had made progress at Kibali while advancing major feasibility studies for the Lumwana and Reko Diq projects. Despite concerns surrounding Barrick's exposure to Mali, Bristow emphasized that the company's fundamental value remains strong.</p>
<p>Barrick also authorized a new $1 billion buyback program, replacing its previous program, which had repurchased $498 million in shares.</p>
<p>For 2025, Barrick expects gold production between 3.15 million and 3.5 million ounces, with all-in-sustaining costs projected between $1,460 and $1,560 per ounce. Capital expenditures are forecasted to be between $3.1 billion and $3.6 billion and copper production is expected to range between 200,000 and 230,000 tonnes, driven by higher output at Lumwana.</p>
<p><strong>GOLD Price Action:</strong> Barrick Gold shares were up 6.47% at $18.18 at the time of writing, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro.</a></p>
<p><figure class="wp-block-image size-large is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent021225&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="1024" height="540" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/12143534/Screenshot-2025-02-12-at-14.35.10-1024x540.png" alt="" class="wp-image-779507" style="width:500px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/12143534/Screenshot-2025-02-12-at-14.35.10-1024x540.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/12143534/Screenshot-2025-02-12-at-14.35.10-300x158.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/12143534/Screenshot-2025-02-12-at-14.35.10-768x405.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/12143534/Screenshot-2025-02-12-at-14.35.10.png 1505w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure></p>
<p><strong>Read Next:</strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/opinion/25/02/43671549/the-perfect-stocks-portfolio-global-value-investing-in-a-changing-worldhttps://www.benzinga.com/opinion/25/02/43671549/the-perfect-stocks-portfolio-global-value-investing-in-a-changing-world">The Perfect Stocks Portfolio: Global Value Investing in a Changing World</a></strong></li>
</ul>
<p><em>Image Via Shutterstock.</em></p>


News

Movers

GOLD

Barrick Gold Shares Gain After Q4 Earnings And New $1 Billion Buyback Program

<p>Deep-pocketed investors have adopted a bullish approach towards Barrick Gold (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GOLD#NYSE">GOLD</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in GOLD usually suggests something big is about to happen.</p>
<p>We gleaned this information from our observations today when Benzinga's options scanner highlighted 30 extraordinary options activities for Barrick Gold. This level of activity is out of the ordinary.</p>
<p>The general mood among these heavyweight investors is divided, with 46% leaning bullish and 43% bearish. Among these notable options, 8 are puts, totaling $398,820, and 22 are calls, amounting to $1,569,465.</p>
<h3>Expected Price Movements</h3>
<p>After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $13.0 and $22.0 for Barrick Gold, spanning the last three months.</p>
<h3>Volume &amp; Open Interest Development</h3>
<p>In terms of liquidity and interest, the mean open interest for Barrick Gold options trades today is 9536.76 with a total volume of 22,863.00.</p>
<p>In the following chart, we are able to follow the development of volume and open interest of call and put options for Barrick Gold's big money trades within a strike price range of $13.0 to $22.0 over the last 30 days.</p>
<h3>Barrick Gold Option Activity Analysis: Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1739391332_0.png" alt="Options Call Chart" /></p>
<h3>Largest Options Trades Observed:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>GOLD</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$2.43</td>
<td>$2.38</td>
<td>$2.42</td>
<td>$16.00</td>
<td>$241.2K</td>
<td>2.4K</td>
<td>1.0K</td>
</tr>
<tr>
<td>GOLD</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$4.3</td>
<td>$4.2</td>
<td>$4.25</td>
<td>$15.00</td>
<td>$210.8K</td>
<td>56.7K</td>
<td>917</td>
</tr>
<tr>
<td>GOLD</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$4.0</td>
<td>$3.95</td>
<td>$3.95</td>
<td>$15.00</td>
<td>$118.5K</td>
<td>1.5K</td>
<td>517</td>
</tr>
<tr>
<td>GOLD</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>03/21/25</td>
<td>$2.26</td>
<td>$2.13</td>
<td>$2.2</td>
<td>$16.00</td>
<td>$110.0K</td>
<td>4.9K</td>
<td>686</td>
</tr>
<tr>
<td>GOLD</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$3.8</td>
<td>$3.7</td>
<td>$3.8</td>
<td>$18.00</td>
<td>$85.1K</td>
<td>881</td>
<td>338</td>
</tr>
</tbody>
</table>
</p>
<h3>About Barrick Gold</h3>
<p>Based in Toronto, Barrick Gold is one of the world's largest gold miners. In 2023, the firm produced nearly 4.1 million attributable ounces of gold and about 420 million pounds of copper. At year-end 2023, Barrick had about two decades of gold reserves along with significant copper reserves. After buying Randgold in 2019 and combining its Nevada mines in a joint venture with competitor Newmont later that year, it operates mines in 19 countries in the Americas, Africa, the Middle East, and Asia. The company also has growing copper exposure. Its potential Reko Diq project in Pakistan, if developed, could double copper production by the end of the decade.</p>
<p>Following our analysis of the options activities associated with Barrick Gold, we pivot to a closer look at the company's own performance.</p>
<h3>Present Market Standing of Barrick Gold</h3>
<ul>
<li>Trading volume stands at 31,893,320, with GOLD's price up by 6.41%, positioned at $18.16.</li>
<li>RSI indicators show the stock to be may be overbought.</li>
<li>Earnings announcement expected in 0 days.</li>
</ul>
<h3>Expert Opinions on Barrick Gold</h3>
<p>Over the past month, 2 industry analysts have shared their insights on this stock, proposing an average target price of $18.5.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from Scotiabank has revised its rating downward to Sector Perform, adjusting the price target to $19.<br />
&#x2A; An analyst from B of A Securities has revised its rating downward to Neutral, adjusting the price target to $18. </p>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for Barrick Gold, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.</p>


Options

Markets

Barrick Gold Unusual Options Activity

<p>Financial giants have made a conspicuous bearish move on Baidu. Our analysis of options history for Baidu (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIDU#NASDAQ">BIDU</a>) revealed 85 unusual trades.</p>
<p>Delving into the details, we found 30% of traders were bullish, while 56% showed bearish tendencies. Out of all the trades we spotted, 6 were puts, with a value of $379,837, and 79 were calls, valued at $5,968,898.</p>
<h3>Projected Price Targets</h3>
<p>After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $60.0 and $170.0 for Baidu, spanning the last three months.</p>
<h3>Insights into Volume &amp; Open Interest</h3>
<p>In today's trading context, the average open interest for options of Baidu stands at 1958.74, with a total volume reaching 33,919.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Baidu, situated within the strike price corridor from $60.0 to $170.0, throughout the last 30 days.</p>
<h3>Baidu 30-Day Option Volume &amp; Interest Snapshot</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1739391327_0.png" alt="Options Call Chart" /></p>
<h3>Noteworthy Options Activity:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>BIDU</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>08/15/25</td>
<td>$10.25</td>
<td>$9.9</td>
<td>$10.0</td>
<td>$100.00</td>
<td>$998.0K</td>
<td>2.9K</td>
<td>1.0K</td>
</tr>
<tr>
<td>BIDU</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$18.65</td>
<td>$18.55</td>
<td>$18.55</td>
<td>$80.00</td>
<td>$371.0K</td>
<td>1.6K</td>
<td>205</td>
</tr>
<tr>
<td>BIDU</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/15/27</td>
<td>$27.9</td>
<td>$26.25</td>
<td>$26.6</td>
<td>$90.00</td>
<td>$266.0K</td>
<td>645</td>
<td>129</td>
</tr>
<tr>
<td>BIDU</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$22.8</td>
<td>$22.2</td>
<td>$22.5</td>
<td>$85.00</td>
<td>$112.4K</td>
<td>510</td>
<td>57</td>
</tr>
<tr>
<td>BIDU</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$10.0</td>
<td>$9.45</td>
<td>$9.93</td>
<td>$90.00</td>
<td>$99.3K</td>
<td>1.2K</td>
<td>431</td>
</tr>
</tbody>
</table>
</p>
<h3>About Baidu</h3>
<p>Baidu is the largest internet search engine in China with over 50% share of the search engine market in 2024 per web analytics firm, Statcounter. The firm generated 72% of core revenue from online marketing services from its search engine in 2023. Outside its search engine, Baidu is a technology-driven company and its other major growth initiatives are artificial intelligence cloud, video streaming services, voice recognition technology, and autonomous driving.</p>
<h3>Present Market Standing of Baidu</h3>
<ul>
<li>With a trading volume of 5,480,640, the price of BIDU is up by 4.6%, reaching $93.55.</li>
<li>Current RSI values indicate that the stock is may be approaching overbought.</li>
<li>Next earnings report is scheduled for 6 days from now.</li>
</ul>
<h3>Professional Analyst Ratings for Baidu</h3>
<p>2 market experts have recently issued ratings for this stock, with a consensus target price of $112.5.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from Barclays has decided to maintain their Equal-Weight rating on Baidu, which currently sits at a price target of $95.<br />
&#x2A; Reflecting concerns, an analyst from Benchmark lowers its rating to Buy with a new price target of $130.</p>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for Baidu, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.</p>


BIDU

Baidu Unusual Options Activity For February 12

<p>Deep-pocketed investors have adopted a bearish approach towards Amgen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in AMGN usually suggests something big is about to happen.</p>
<p>We gleaned this information from our observations today when Benzinga's options scanner highlighted 9 extraordinary options activities for Amgen. This level of activity is out of the ordinary.</p>
<p>The general mood among these heavyweight investors is divided, with 33% leaning bullish and 66% bearish. Among these notable options, 6 are puts, totaling $210,150, and 3 are calls, amounting to $161,431.</p>
<h3>Expected Price Movements</h3>
<p>Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $280.0 to $305.0 for Amgen over the last 3 months. </p>
<h3>Analyzing Volume &amp; Open Interest</h3>
<p>In terms of liquidity and interest, the mean open interest for Amgen options trades today is 448.17 with a total volume of 924.00.</p>
<p>In the following chart, we are able to follow the development of volume and open interest of call and put options for Amgen's big money trades within a strike price range of $280.0 to $305.0 over the last 30 days.</p>
<h3>Amgen Call and Put Volume: 30-Day Overview</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1739391322_0.png" alt="Options Call Chart" /></p>
<h3>Largest Options Trades Observed:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th align="right"><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>AMGN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$3.45</td>
<td>$3.25</td>
<td>$3.45</td>
<td>$305.00</td>
<td>$107.2K</td>
<td align="right">318</td>
<td align="right">408</td>
</tr>
<tr>
<td>AMGN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$9.0</td>
<td>$8.35</td>
<td>$9.0</td>
<td>$300.00</td>
<td>$47.7K</td>
<td align="right">344</td>
<td align="right">53</td>
</tr>
<tr>
<td>AMGN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$9.0</td>
<td>$8.95</td>
<td>$9.0</td>
<td>$300.00</td>
<td>$42.3K</td>
<td align="right">344</td>
<td align="right">100</td>
</tr>
<tr>
<td>AMGN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$13.5</td>
<td>$13.35</td>
<td>$13.5</td>
<td>$290.00</td>
<td>$33.7K</td>
<td align="right">675</td>
<td align="right">54</td>
</tr>
<tr>
<td>AMGN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$13.65</td>
<td>$13.45</td>
<td>$13.5</td>
<td>$290.00</td>
<td>$31.0K</td>
<td align="right">675</td>
<td align="right">85</td>
</tr>
</tbody>
</table>
</p>
<h3>About Amgen</h3>
<p>Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.</p>
<p>Having examined the options trading patterns of Amgen, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance</p>
<h3>Present Market Standing of Amgen</h3>
<ul>
<li>With a volume of 1,356,099, the price of AMGN is down -0.63% at $294.81. </li>
<li>RSI indicators hint that the underlying stock may be approaching overbought.</li>
<li>Next earnings are expected to be released in 78 days.</li>
</ul>
<h3>What Analysts Are Saying About Amgen</h3>
<p>Over the past month, 4 industry analysts have shared their insights on this stock, proposing an average target price of $305.75.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; Maintaining their stance, an analyst from B of A Securities continues to hold a Underperform rating for Amgen, targeting a price of $275.<br />
&#x2A; Consistent in their evaluation, an analyst from Citigroup keeps a Neutral rating on Amgen with a target price of $295.<br />
&#x2A; An analyst from RBC Capital downgraded its action to Outperform with a price target of $324.<br />
&#x2A; An analyst from Piper Sandler persists with their Overweight rating on Amgen, maintaining a target price of $329. </p>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Amgen with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.</p>


AMGN

Amgen Unusual Options Activity For February 12

VALE

Brazil Presidential Palace Says Vale To Announce 70 Billion Reais Investment For 2025-2030 In Copper, Iron Ore In Brazil's Carajas; Vale's Investment Announcement To Be Made At Event On Friday With Brazil's President Lula

WIIM

GRAL

GRAIL shares are trading lower after the company announced the initial phase of a program to improve provider access to GRAIL's Galleri multi-cancer early detection test.

CSX Corp 13G Filing Shows JPMorgan Chase & Co. Reported A 5.5% Stake In The Co As Of December 31, 2024

<p>After a stellar 2024 and an outstanding first month of 2025, the world has again caught the gold bug. Geopolitical tensions, escalating tariff threats and fears of reappearing inflation have prompted <a href="https://www.benzinga.com/news/global/25/02/43514005/escalating-tariff-wars-tighter-african-supply-drive-gold-toward-3000-milestone">demand for physical metal</a>, causing disruptions, delays and sale suspensions.</p>
<p>South Korea is the latest country to face such a challenge. According <a href="https://www.bloomberg.com/news/articles/2025-02-12/south-korea-s-mint-halts-gold-bar-sales-as-supply-tightens">to</a> Bloomberg, the <strong>Korea Minting and Security Printing Corp</strong>, a state-owned coin issuer, has suspended sales.</p>
<p>Earlier this month, London's Gold Forward Offered Rate (GOFO) surged to 10% annually, far above the typical 2-3%. A supply shortage caused the <strong>Bank of England</strong> to announce <a href="https://in.benzinga.com/news/econ-s/25/01/43348204/gold-hits-record-high-as-central-banks-ease-stance-5-mining-stocks-rally">multi-week delivery delays</a>, prompting its gold to trade at a discount of over $5 per ounce compared to London&#8217;s spot price.</p>
<p>However, as institutions rush to move gold overseas, the logistical challenge of converting London&#8217;s 400-ounce bars into smaller, Comex-approved counterparts has added to delays. Leasing rates have also spiked to 4.7%, with central banks capitalizing on the demand by lending gold at higher premiums.</p>
<p>In 2024, these financial institutions added 1,045 tons of gold to their reserves <a href="https://www.gold.org/goldhub/research/gold-demand-trends/gold-demand-trends-full-year-2024/central-banks">per</a> World Gold Council. <strong>Barrick Gold</strong>'s CEO <strong>Mark Bristow</strong> noted that "gold is becoming reserve currency for central banks" during the leading gold miner's Q4 earnings webcast.</p>
<p>Beyond short-term supply constraints, fears of a second wave of inflation add to gold's appeal. Today's 3% CPI came in hotter than expected, marking the fourth consecutive increase in annual inflation.</p>
<p>While another wave of global inflation is not inevitable, analysts at <strong>ING Research</strong> believe that inflation will be <a href="https://www.ing.com/Newsroom/News/Inflations-second-wave-Are-we-really-watching-a-70s-rerun.htm">structurally higher</a> and more volatile within the next years. However, they acknowledge that the past is not a perfect gauge for the future, given the vastly different environment preceding the inflation period, with two recessions and oil shocks.</p>
<p>Still, the domestic economy structure also looked vastly different back then. Through the 1970s, the government ran an average yearly <a href="https://clintonwhitehouse4.archives.gov/WH/New/html/surplus2.html">budget deficit of 2.7%</a>. In 2024, the deficit was 6.4%, while the Congressional Budget Office saw it at 6.5% in 2025. To plug this hole, the government needs to sell bonds and if the Federal Reserve is the buyer, directly or through programs like Quantitative Easing, the money supply grows, usually taking inflation along.</p>
<p><strong>Read Next</strong>: <a href="https://www.benzinga.com/25/02/43651098/geopolitics-and-resource-nationalism-are-choking-the-commodity-supply">Geopolitics And Resource Nationalism Are Choking The Commodity Supply</a></p>
<p><em>Photo: Shutterstock</em></p>


Macro Economic Events

Commodities

Global

Economics

Inflation's Second-Wave Fears And Budget Deficits Support Gold's Record Pace

<p>Crypto markets are stabilizing and trending <a href="https://www.benzinga.com/markets/cryptocurrency/25/02/43667278/bitcoin-sees-short-term-volatility-after-inflation-data-altseason-remains-distant">upward after an initial drop</a> following the higher-than-expected COnsumer Price Inflation report.</p>
<p><figure class="wp-block-table"><br />
<table>
<tbody>
<tr>
<td><strong>Cryptocurrency</strong></td>
<td><strong>Price&nbsp;&nbsp;&nbsp;</strong></td>
<td><strong>Gains +/-</strong></td>
</tr>
<tr>
<td><strong>Bitcoin</strong> (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>)</td>
<td>&nbsp;$97,166.74</td>
<td>+2.2%</td>
</tr>
<tr>
<td><strong>Ethereum</strong> (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>)</td>
<td>&nbsp;$2,679.72</td>
<td>+3.4%</td>
</tr>
<tr>
<td><strong>Solana</strong> (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>)</td>
<td>&nbsp;$193.42</td>
<td>-1%</td>
</tr>
<tr>
<td><strong>XRP </strong>(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xrp/usd">XRP</a>)</td>
<td>&nbsp;$2.44</td>
<td>+2.7%</td>
</tr>
<tr>
<td><strong>Dogecoin</strong> (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>)</td>
<td>&nbsp;$0.2612</td>
<td>+4.6%</td>
</tr>
<tr>
<td><strong>Shiba Inu</strong> (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/shib/usd">SHIB</a>)</td>
<td>&nbsp;$0.00001680</td>
<td>+8.4%</td>
</tr>
</tbody>
</table>
<p></p></figure></p>
<p><strong>Notable Statistics:</strong></p>
<ul>
<li>IntoTheBlock data shows large transaction volume increased by 3.2% and daily active addresses grew by 2.6%. Transactions greater than $100,000 are up from 9,866 to 10,487 in a single day. Exchanges netflows are down by 192.3%.</li>
<li>Coinglass data reports 142,147 traders were liquidated in the past 24 hours for $310.39 million.</li>
<li>IntoTheBlock <a href="https://x.com/intotheblock/status/1889602444167918050">data</a> points out that the 1.6 million addresses that historically acquired 1.57 million BTC at an average price of 97,200 are now forming a resistance level. It also added that "these holders may sell near their breakeven amid market uncertainty, adding selling pressure and complicating any clear upward breakout."</li>
</ul>
<p><strong>Notable Developments:</strong></p>
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/02/43667642/coinbase-expected-to-post-strong-earnings-as-trading-volume-hits-multi-year-high">Coinbase Expected To Post Strong Earnings As Trading Volume Hits Multi-Year High</a></li>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/02/43646818/goldman-sachs-increases-bitcoin-etf-stake-over-1-5-billion-in-q4-reports-a-massive-1793-jump-in-ethereum-etf-holdings">Goldman Sachs Increases Bitcoin ETF Stake Over $1.5 Billion In Q4, Reports A Massive 1793% Jump In Ethereum ETF Holdings</a></li>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/02/43658023/trump-to-nominate-ex-cftc-commissioner-brian-quintenz-as-agency-head">Trump To Nominate Ex-CFTC Commissioner Brian Quintenz As Agency Head</a></li>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/02/43654402/el-salvador-proved-bitcoin-is-not-destined-to-be-money-analyst-says">El Salvador Proved &#8216;Bitcoin Is Not Destined To Be Money,&#8217; Analyst Says</a></li>
</ul>
<p><strong>Top Gainers:</strong></p>
<p><figure class="wp-block-table"><br />
<table>
<tbody>
<tr>
<td><strong>Cryptocurrency</strong></td>
<td><strong>Price&nbsp;&nbsp;&nbsp;</strong></td>
<td><strong>Gains +/-</strong></td>
</tr>
<tr>
<td><strong>PancakeSwap</strong> (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/cake/usd">CAKE</a>)</td>
<td>&nbsp;$2.63</td>
<td>+37.2%</td>
</tr>
<tr>
<td><strong>Sonic</strong> (CRYPTO: S)</td>
<td>&nbsp;$0.5459</td>
<td>+23.7%</td>
</tr>
<tr>
<td><strong>Onyxcoin</strong> (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">XCN</a>)</td>
<td>&nbsp;$0.02332</td>
<td>+11.3%</td>
</tr>
</tbody>
</table>
<p></p></figure></p>
<p><strong>Trader Notes: </strong>With Bitcoin prices resuming uptrend, crypto trader DonAlt predicts its Bitcoin's time to break out.</p>
<p><figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"><br />
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true"><p lang="en" dir="ltr"><a href="https://twitter.com/search?q=%24BTC&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$BTC</a><br /><br />Time to break out <a href="https://t.co/NPSTi8pbh7">pic.twitter.com/NPSTi8pbh7</a></p>
<p>&mdash; DonAlt (@CryptoDonAlt) <a href="https://twitter.com/CryptoDonAlt/status/1889717070536835492?ref_src=twsrc%5Etfw">February 12, 2025</a></p></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
<p></p></figure></p>
<p>Crypto Chase <a href="https://x.com/Crypto_Chase/status/1889740312215515464">explained</a> that he is still holding Bitcoin long position from $95,600 after having survived 8 days of chop and the CPI release. </p>
<p>He sees prices at local resistance, but traders are looking to take profits higher. </p>
<p>The trader moved his stop loss to around $94,000 as local liquidity was swept and demand held, making a return to the lows unlikely.</p>
<p>Crypto trader Jelle sees Bitcoin is retesting mini range and a bounce will take it back to 100,000 while Scient <a href="https://x.com/Crypto_Scient/status/1889759391647150284">highlighted</a> on Bitcoin is showing strength on a bearish news, which is a net positive outlook in the near term.</p>
<p><figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"><br />
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true"><p lang="en" dir="ltr">Retesting mini range.<br /><br />Bounce here and we charge back to $100,000 next.<a href="https://twitter.com/hashtag/Bitcoin?src=hash&amp;ref_src=twsrc%5Etfw">#Bitcoin</a> <a href="https://t.co/wMpCh0PKKe">pic.twitter.com/wMpCh0PKKe</a></p>
<p>&mdash; Jelle (@CryptoJelleNL) <a href="https://twitter.com/CryptoJelleNL/status/1889757090941403604?ref_src=twsrc%5Etfw">February 12, 2025</a></p></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
<p></p></figure></p>
<p><strong>Read Next:&nbsp;</strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/markets/cryptocurrency/25/02/43662831/bitcoin-meme-coins-dominate-crypto-but-other-projects-suffer-analyst-says">Bitcoin, Meme Coins Dominate Crypto, But Other Projects Suffer, Analyst Says</a></strong></li>
</ul>
<p><em>Image: Shutterstock</em></p>


Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

$CAKE

$DOGE

$ETH

$JTO

$SHIB

$SOL

$XCN

$XRP

Bitcoin, Ethereum, XRP, Dogecoin Climb Higher As Inflation Volatility Eases: 'Don't See A Reason To Go Back To Lows,' Trader Says

<p><strong>AMC Entertainment Holdings, Inc.</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMC#NYSE">AMC</a>) stock is trading higher on Wednesday after Goldman Sachs disclosed a stake <a href="https://www.benzinga.com//node/43665086">in the company</a>.</p>
<p><strong>The Details:</strong> Through a 13G filing with the Securities and Exchange Commission (SEC), Goldman revealed a 6.5% stake in AMC as of December 31. The stake is equal to roughly 24,420,283 shares.</p>
<p>Back in early December, AMC <a href="http://Back in early December, AMC entered into a sales agreement with Goldman Sachs, allowing it to sell up to 50 million Class A shares directly to the firm. AMC said it planned to use the proceeds from the agreement to strengthen its balance sheet and reinvest in its core business.">entered</a> into a sales agreement with Goldman, allowing it to sell up to 50 million Class A shares directly to the firm. The company said it planned to use the proceeds from the agreement to strengthen its balance sheet and reinvest in its core business.</p>
<p><strong>What Else:</strong> AMC is expected to release its earnings for the 2024 fiscal-year fourth-quarter on February 25. Analysts estimate a loss of 18 cents per share and revenue of $1.33 billion.</p>
<p>Ahead of earnings, Roth MKM analyst <strong>Eric Handler </strong>upgraded AMC from a Sell rating to a Neutral rating and lowered the price target from&nbsp;$4&nbsp;to&nbsp;$3.25.</p>
<p><strong>How To Buy AMC Shares</strong></p>
<p>Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. </p>
<p>For example, in AMC's case, it is in the Communication Services sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.</p>
<p><strong>Related Link: <a href="https://www.benzinga.com/insights/analyst-ratings/25/02/43670516/the-analyst-verdict-kilroy-realty-in-the-eyes-of-7-experts">The Analyst Verdict: Kilroy Realty In The Eyes Of 7 Experts</a></strong></p>
<p><strong>AMC Price Action</strong>: At the time of writing, AMC shares are trading 6.04% higher at $3.50, according to data from <a href="https://www.benzinga.com/pro/">Benzinga Pro.</a></p>
<p><em>Image: via Shutterstock</em></p>


What's Going On With AMC Shares Wednesday?

<p><a href="https://x.com/Capitol_Forum/status/1889756301325996124" title="https://x.com/Capitol_Forum/status/1889756301325996124">https://x.com/Capitol_Forum/status/1889756301325996124</a></p>


OSCR

CORRECTION: Watching Oscar Health; The Capitol Forum Posts On X "Oscar Health Accused Of Misusing No Surprises Act To Delay Payments, Underpaying CA Health Systems"

<p>Curbline Properties (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CURB#NYSE">CURB</a>) underwent analysis by 4 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.</p>
<p>The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $27.0, along with a high estimate of $31.00 and a low estimate of $24.00. Witnessing a positive shift, the current average has risen by 3.85% from the previous average price target of $26.00.</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1739390462_0.png" alt="price target chart" /></p>
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
<p>The standing of Curbline Properties among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alex Goldfarb</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$31.00</td>
<td>$28.00</td>
</tr>
<tr>
<td>Floris Van Dijkum</td>
<td>Compass Point</td>
<td>Raises</td>
<td>Neutral</td>
<td>$26.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Ronald Kamdem</td>
<td>Morgan Stanley</td>
<td>Announces</td>
<td>Equal-Weight</td>
<td>$27.00</td>
<td>-</td>
</tr>
<tr>
<td>Floris Van Dijkum</td>
<td>Compass Point</td>
<td>Announces</td>
<td>Neutral</td>
<td>$24.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Curbline Properties. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Curbline Properties compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts gauge the dynamics of price targets, providing estimates for the future value of Curbline Properties's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Curbline Properties's market standing. Stay informed and make well-considered decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/CURB/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Curbline Properties analyst ratings.</strong></a></p>
<h2>About Curbline Properties</h2>
<p>Curbline Properties Corp is a publicly-traded REIT operating Convenience retail properties, offering enhanced access and visibility relative to other retail property types. The properties generally consist of a ubiquitous row of shop units along with dedicated parking leased to a diversified mixture of national and local service and restaurant tenants that cater to daily convenience trips from the growing suburban population.</p>
<h3>Key Indicators: Curbline Properties's Financial Health</h3>
<p><strong>Market Capitalization Analysis:</strong> Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> Over the 3 months period, Curbline Properties showcased positive performance, achieving a revenue growth rate of <strong>22.92%</strong> as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Real Estate sector.</p>
<p><strong>Net Margin:</strong> Curbline Properties's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of <strong>-52.1%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Curbline Properties's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of <strong>-1.14%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Return on Assets (ROA):</strong> Curbline Properties's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of <strong>-1.1%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Debt Management:</strong> The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at <strong>0.03</strong>.</p>
<h2>The Basics of Analyst Ratings</h2>
<p>Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.</p>
<p>Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Analyst Ratings

CURB

Analyst Expectations For Curbline Properties's Future

<p>In the latest quarter, 4 analysts provided ratings for Staar Surgical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STAA#NASDAQ">STAA</a>), showcasing a mix of bullish and bearish perspectives.</p>
<p>The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $23.0, a high estimate of $28.00, and a low estimate of $16.00. Observing a downward trend, the current average is 32.85% lower than the prior average price target of $34.25. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1739390453_0.png" alt="price target chart" /></p>
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
<p>An in-depth analysis of recent analyst actions unveils how financial experts perceive Staar Surgical. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Thomas Stephan</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$20.00</td>
<td>$38.00</td>
</tr>
<tr>
<td>Mason Carrico</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Equal-Weight</td>
<td>$28.00</td>
<td>$28.00</td>
</tr>
<tr>
<td>Matt O'Brien</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$16.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Jon Young</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Hold</td>
<td>$28.00</td>
<td>$31.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Staar Surgical. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Staar Surgical compared to the broader market.</li>
<li><strong>Price Targets:</strong> Gaining insights, analysts provide estimates for the future value of Staar Surgical's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Staar Surgical's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/STAA/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Staar Surgical analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.</p>
<h2>All You Need to Know About Staar Surgical</h2>
<p>Staar Surgical Co is a manufacturer of lenses. It designs, develops, manufactures, and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. The company also makes lenses that are used in surgery to treat cataracts. The company offers two types of products: Implantable Collamer lenses (ICL) and intraocular lens (IOL). The ICLs are used in refractive surgery and IOLs are used in cataract surgery. The majority of sales are generated from the ophthalmic surgical product segment.</p>
<h3>A Deep Dive into Staar Surgical's Financials</h3>
<p><strong>Market Capitalization Analysis:</strong> Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> Staar Surgical's remarkable performance in 3 months is evident. As of 30 September, 2024, the company achieved an impressive revenue growth rate of <strong>10.31%</strong>. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.</p>
<p><strong>Net Margin:</strong> Staar Surgical's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of <strong>11.27%,</strong> the company showcases strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Staar Surgical's ROE excels beyond industry benchmarks, reaching <strong>2.38%</strong>. This signifies robust financial management and efficient use of shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Staar Surgical's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of <strong>1.9%,</strong> the company showcases efficient use of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> With a below-average debt-to-equity ratio of <strong>0.09</strong>, Staar Surgical adopts a prudent financial strategy, indicating a balanced approach to debt management.</p>
<h2>Understanding the Relevance of Analyst Ratings</h2>
<p>Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


STAA

Analyst Expectations For Staar Surgical's Future

<p>Ratings for OneStream (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OS#NASDAQ">OS</a>) were provided by 8 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.</p>
<p>The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">3</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $34.88, a high estimate of $40.00, and a low estimate of $26.00. A decline of 2.21% from the prior average price target is evident in the current average. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1739390446_0.png" alt="price target chart" /></p>
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
<p>An in-depth analysis of recent analyst actions unveils how financial experts perceive OneStream. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Daniel Jester</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$34.00</td>
<td>$38.00</td>
</tr>
<tr>
<td>John Difucci</td>
<td>Guggenheim</td>
<td>Maintains</td>
<td>Buy</td>
<td>$35.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>Scott Berg</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$38.00</td>
<td>$38.00</td>
</tr>
<tr>
<td>Mark Murphy</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$26.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Steven Enders</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$32.00</td>
<td>$36.00</td>
</tr>
<tr>
<td>Chris Quintero</td>
<td>Morgan Stanley</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$37.00</td>
<td>$37.00</td>
</tr>
<tr>
<td>Daniel Ives</td>
<td>Wedbush</td>
<td>Announces</td>
<td>Outperform</td>
<td>$40.00</td>
<td>-</td>
</tr>
<tr>
<td>Adam Hotchkiss</td>
<td>Goldman Sachs</td>
<td>Announces</td>
<td>Buy</td>
<td>$37.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to OneStream. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of OneStream compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts provide insights into price targets, offering estimates for the future value of OneStream's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of OneStream's market position. Stay informed and make well-informed decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/OS/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on OneStream analyst ratings.</strong></a></p>
<h2>Discovering OneStream: A Closer Look</h2>
<p>OneStream Inc is an AI-enabled and extensible software platform that unifies core financial functions and broader operational data and processes within a single platform. The Digital Finance Cloud of the company provides a comprehensive, dynamic, and predictive view of the entire enterprise, providing corporate leaders the control, visibility, and agility required to proactively adjust business and day-to-day execution.</p>
<h3>Key Indicators: OneStream's Financial Health</h3>
<p><strong>Market Capitalization:</strong> Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.</p>
<p><strong>Revenue Growth:</strong> OneStream displayed positive results in 3 months. As of 30 September, 2024, the company achieved a solid revenue growth rate of approximately <strong>20.69%</strong>. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Information Technology sector.</p>
<p><strong>Net Margin:</strong> The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of <strong>-133.14%,</strong> the company may need to address challenges in effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of <strong>-80.43%,</strong> the company may need to address challenges in generating satisfactory returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> OneStream's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of <strong>-30.44%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Debt Management:</strong> OneStream's debt-to-equity ratio is below the industry average. With a ratio of <b>0.06</b>, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.</p>
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
<p>Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.</p>
<p>Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Beyond The Numbers: 8 Analysts Discuss OneStream Stock

<p>21 analysts have shared their evaluations of Exelixis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXEL#NASDAQ">EXEL</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.</p>
<p>The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">7</td>
<td align="right">7</td>
<td align="right">7</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">3</td>
<td align="right">6</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>In the assessment of 12-month price targets, analysts unveil insights for Exelixis, presenting an average target of $38.71, a high estimate of $45.00, and a low estimate of $29.00. Surpassing the previous average price target of $35.67, the current average has increased by 8.52%.</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1739390435_0.png" alt="price target chart" /></p>
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
<p>The standing of Exelixis among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>David Lebowitz</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$45.00</td>
<td>$38.00</td>
</tr>
<tr>
<td>Michael Schmidt</td>
<td>Guggenheim</td>
<td>Maintains</td>
<td>Buy</td>
<td>$42.00</td>
<td>$42.00</td>
</tr>
<tr>
<td>Sudan Loganathan</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Equal-Weight</td>
<td>$29.00</td>
<td>$29.00</td>
</tr>
<tr>
<td>Stephen Willey</td>
<td>Stifel</td>
<td>Raises</td>
<td>Hold</td>
<td>$36.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Joseph Catanzaro</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$38.00</td>
<td>$37.00</td>
</tr>
<tr>
<td>Ashwani Verma</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$34.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Silvan Tuerkcan</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$41.00</td>
<td>$41.00</td>
</tr>
<tr>
<td>Asthika Goonewardene</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$43.00</td>
<td>$42.00</td>
</tr>
<tr>
<td>Sudan Loganathan</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Equal-Weight</td>
<td>$29.00</td>
<td>$29.00</td>
</tr>
<tr>
<td>Robert Burns</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$40.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Jefferson Harralson</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$40.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Jay Olson</td>
<td>Oppenheimer</td>
<td>Lowers</td>
<td>Perform</td>
<td>$33.00</td>
<td>$41.00</td>
</tr>
<tr>
<td>Silvan Tuerkcan</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$41.00</td>
<td>$41.00</td>
</tr>
<tr>
<td>Jay Olson</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$41.00</td>
<td>$38.00</td>
</tr>
<tr>
<td>Asthika Goonewardene</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$42.00</td>
<td>$38.00</td>
</tr>
<tr>
<td>Silvan Tuerkcan</td>
<td>JMP Securities</td>
<td>Raises</td>
<td>Market Outperform</td>
<td>$41.00</td>
<td>$34.00</td>
</tr>
<tr>
<td>Joseph Catanzaro</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$37.00</td>
<td>$36.00</td>
</tr>
<tr>
<td>Robert Burns</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$40.00</td>
<td>$29.00</td>
</tr>
<tr>
<td>Michael Schmidt</td>
<td>Guggenheim</td>
<td>Raises</td>
<td>Buy</td>
<td>$42.00</td>
<td>$33.00</td>
</tr>
<tr>
<td>Etzer Darout</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$40.00</td>
<td>$36.00</td>
</tr>
<tr>
<td>Jason Gerberry</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Neutral</td>
<td>$39.00</td>
<td>$35.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Exelixis. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Exelixis compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts explore the dynamics of price targets, providing estimates for the future value of Exelixis's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
<p>Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Exelixis's market standing. Stay informed and make data-driven decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/EXEL/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Exelixis analyst ratings.</strong></a></p>
<h2>Unveiling the Story Behind Exelixis</h2>
<p>Exelixis is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.</p>
<h3>Exelixis: Financial Performance Dissected</h3>
<p><strong>Market Capitalization:</strong> With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.</p>
<p><strong>Revenue Growth:</strong> Exelixis's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately <strong>14.33%</strong>. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.</p>
<p><strong>Net Margin:</strong> Exelixis's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>21.87%</strong> net margin, the company effectively manages costs and achieves strong profitability.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of <strong>5.37%,</strong> the company showcases effective utilization of equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Exelixis's ROA excels beyond industry benchmarks, reaching <strong>4.12%</strong>. This signifies efficient management of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at <strong>0.09</strong>.</p>
<h2>How Are Analyst Ratings Determined?</h2>
<p>Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.</p>
<p>Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


EXEL

A Glimpse Into The Expert Outlook On Exelixis Through 21 Analysts

<p>Providing a diverse range of perspectives from bullish to bearish, 12 analysts have published ratings on Fidelity National Info (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FIS#NYSE">FIS</a>) in the last three months.</p>
<p>The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">2</td>
<td align="right">4</td>
<td align="right">6</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts have recently evaluated Fidelity National Info and provided 12-month price targets. The average target is $94.0, accompanied by a high estimate of $126.00 and a low estimate of $80.00. Experiencing a 6.0% decline, the current average is now lower than the previous average price target of $100.00. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1739390427_0.png" alt="price target chart" /></p>
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
<p>A comprehensive examination of how financial experts perceive Fidelity National Info is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Timothy Chiodo</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$81.00</td>
<td>$94.00</td>
</tr>
<tr>
<td>Daniel Perlin</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$95.00</td>
<td>$104.00</td>
</tr>
<tr>
<td>Andrew Bauch</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$80.00</td>
<td>$88.00</td>
</tr>
<tr>
<td>James Friedman</td>
<td>Susquehanna</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$81.00</td>
<td>$103.00</td>
</tr>
<tr>
<td>Charles Nabhan</td>
<td>Stephens &amp; Co.</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$90.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Dominick Gabriele</td>
<td>Compass Point</td>
<td>Lowers</td>
<td>Buy</td>
<td>$113.00</td>
<td>$126.00</td>
</tr>
<tr>
<td>James Faucette</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$86.00</td>
<td>$92.00</td>
</tr>
<tr>
<td>Vasundhara Govil</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$92.00</td>
<td>$102.00</td>
</tr>
<tr>
<td>Daniel Perlin</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$104.00</td>
<td>$104.00</td>
</tr>
<tr>
<td>Andrew Bauch</td>
<td>Wells Fargo</td>
<td>Announces</td>
<td>Equal-Weight</td>
<td>$88.00</td>
<td>-</td>
</tr>
<tr>
<td>James Faucette</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$92.00</td>
<td>$87.00</td>
</tr>
<tr>
<td>Dominick Gabriele</td>
<td>Compass Point</td>
<td>Announces</td>
<td>Buy</td>
<td>$126.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Fidelity National Info. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Fidelity National Info compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
<p>Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Fidelity National Info's market standing. Stay informed and make data-driven decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/FIS/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Fidelity National Info analyst ratings.</strong></a></p>
<h2>About Fidelity National Info</h2>
<p>Fidelity National Information Services provides core processing and ancillary services to banks, but its business has expanded over time. By acquiring SunGard in 2015, the company now provides record-keeping and other services to investment firms. With the acquisition of Worldpay in 2019, FIS was providing payment processing services for merchants and holding leading positions in the United States and United Kingdom. But the company sold off a majority interest in Worldpay and now has only a minority stake.</p>
<h3>Fidelity National Info's Economic Impact: An Analysis</h3>
<p><strong>Market Capitalization Analysis:</strong> The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.</p>
<p><strong>Revenue Growth:</strong> Over the 3 months period, Fidelity National Info showcased positive performance, achieving a revenue growth rate of <strong>3.13%</strong> as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Financials sector.</p>
<p><strong>Net Margin:</strong> The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of <strong>8.72%,</strong> the company may need to address challenges in effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> Fidelity National Info's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of <strong>1.33%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> Fidelity National Info's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of <strong>0.65%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Debt Management:</strong> With a below-average debt-to-equity ratio of <strong>0.66</strong>, Fidelity National Info adopts a prudent financial strategy, indicating a balanced approach to debt management.</p>
<h2>The Basics of Analyst Ratings</h2>
<p>Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. </p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p>If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


A Glimpse Into The Expert Outlook On Fidelity National Info Through 12 Analysts

<p><strong>AMETEK's</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AME#NYSE">AME</a>) short percent of float has fallen 7.69% since its last report. The company recently reported that it has <strong>1.97 million shares sold short</strong>, which is 0.96% of all regular shares that are available for trading. Based on its trading volume, <strong>it would take traders 1.28 days to cover their short positions on average.</strong></p>
<h3>Why Short Interest Matters</h3>
<p>Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.</p>
<p>Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.</p>
<p><strong>See Also:</strong> <a href="https://www.benzinga.com/short-interest"><strong>List of the most shorted stocks</strong></a></p>
<h3>AMETEK Short Interest Graph (3 Months)</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1739390424_0.png" alt="short_fig" /></p>
<p>As you can see from the chart above the percentage of shares that are sold short for AMETEK has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.</p>
<h3>Comparing AMETEK's Short Interest Against Its Peers</h3>
<p>Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.</p>
<p>According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, AMETEK's peer group average for short interest as a percentage of float is 10.42%, which means the company has <strong>less</strong> short interest than most of its peers.</p>
<p>Did you know that increasing short interest can actually be <strong>bullish</strong> for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/"><strong>This post by Benzinga Money explains how you can profit from it.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and was reviewed by an editor.</em></p>


Short Sellers

Short Ideas

Trading Ideas

Looking Into AMETEK's Recent Short Interest

<p><strong>Carpenter Tech's</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRS#NYSE">CRS</a>) short percent of float has risen 11.25% since its last report. The company recently reported that it has <strong>2.79 million shares sold short</strong>, which is 7.81% of all regular shares that are available for trading. Based on its trading volume, <strong>it would take traders 3.42 days to cover their short positions on average.</strong></p>
<h3>Why Short Interest Matters</h3>
<p>Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.</p>
<p>Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.</p>
<p><strong>See Also:</strong> <a href="https://www.benzinga.com/short-interest"><strong>List of the most shorted stocks</strong></a></p>
<h3>Carpenter Tech Short Interest Graph (3 Months)</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1739390418_0.png" alt="short_fig" /></p>
<p>As you can see from the chart above the percentage of shares that are sold short for Carpenter Tech has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.</p>
<h3>Comparing Carpenter Tech's Short Interest Against Its Peers</h3>
<p>Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.</p>
<p>According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Carpenter Tech's peer group average for short interest as a percentage of float is 4.85%, which means the company has <strong>more</strong> short interest than most of its peers.</p>
<p>Did you know that increasing short interest can actually be <strong>bullish</strong> for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/"><strong>This post by Benzinga Money explains how you can profit from it.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and was reviewed by an editor.</em></p>


Looking Into Carpenter Tech's Recent Short Interest

<p>Teradata (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDC#NYSE">TDC</a>) has been analyzed by 5 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.</p>
<p>In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $30.6, along with a high estimate of $37.00 and a low estimate of $25.00. A 10.0% drop is evident in the current average compared to the previous average price target of $34.00. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1739390416_0.png" alt="price target chart" /></p>
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
<p>The standing of Teradata among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Matthew Hedberg</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$29.00</td>
<td>$32.00</td>
</tr>
<tr>
<td>Howard Ma</td>
<td>Guggenheim</td>
<td>Lowers</td>
<td>Buy</td>
<td>$37.00</td>
<td>$42.00</td>
</tr>
<tr>
<td>Chirag Ved</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$32.00</td>
<td>$37.00</td>
</tr>
<tr>
<td>Raimo Lenschow</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$25.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Raimo Lenschow</td>
<td>Barclays</td>
<td>Raises</td>
<td>Underweight</td>
<td>$30.00</td>
<td>$29.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Teradata. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Teradata compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts explore the dynamics of price targets, providing estimates for the future value of Teradata's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
<p>To gain a panoramic view of Teradata's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/TDC/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Teradata analyst ratings.</strong></a></p>
<h2>About Teradata</h2>
<p>Teradata Corp provides analytic data products and related services. The Company operates in data and analytics, which captures, integrates, stores, manages, and analyzes data of all types to answer business questions and deliver insight; and marketing applications, which offer marketing management products to help businesses win customer loyalty. Its solutions include components such as data warehousing, Asset optimization, Fraud prevention, Product innovation, and risk mitigation. A majority of the firm's revenue is generated in the United States.</p>
<h3>Teradata: Financial Performance Dissected</h3>
<p><strong>Market Capitalization:</strong> Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.</p>
<p><strong>Revenue Growth:</strong> Teradata's remarkable performance in 3 months is evident. As of 30 September, 2024, the company achieved an impressive revenue growth rate of <strong>0.46%</strong>. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Information Technology sector, the company faces challenges, achieving a growth rate lower than the average among peers.</p>
<p><strong>Net Margin:</strong> Teradata's net margin is impressive, surpassing industry averages. With a net margin of <strong>7.27%,</strong> the company demonstrates strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Teradata's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of <strong>32.0%,</strong> the company showcases efficient use of equity capital and strong financial health.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of <strong>1.95%,</strong> the company showcases effective utilization of assets.</p>
<p><strong>Debt Management:</strong> The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of <strong>4.74</strong>, caution is advised due to increased financial risk.</p>
<h2>Analyst Ratings: Simplified</h2>
<p>Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.</p>
<p>Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


5 Analysts Have This To Say About Teradata

<p><strong>United Parcel Service's</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UPS#NYSE">UPS</a>) short percent of float has risen 35.5% since its last report. The company recently reported that it has <strong>16.73 million shares sold short</strong>, which is 2.29% of all regular shares that are available for trading. Based on its trading volume, <strong>it would take traders 1.93 days to cover their short positions on average.</strong></p>
<h3>Why Short Interest Matters</h3>
<p>Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.</p>
<p>Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.</p>
<p><strong>See Also:</strong> <a href="https://www.benzinga.com/short-interest"><strong>List of the most shorted stocks</strong></a></p>
<h3>United Parcel Service Short Interest Graph (3 Months)</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1739390413_0.png" alt="short_fig" /></p>
<p>As you can see from the chart above the percentage of shares that are sold short for United Parcel Service has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.</p>
<h3>Comparing United Parcel Service's Short Interest Against Its Peers</h3>
<p>Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.</p>
<p>According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, United Parcel Service's peer group average for short interest as a percentage of float is 3.12%, which means the company has <strong>less</strong> short interest than most of its peers.</p>
<p>Did you know that increasing short interest can actually be <strong>bullish</strong> for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/"><strong>This post by Benzinga Money explains how you can profit from it.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and was reviewed by an editor.</em></p>


Peering Into United Parcel Service's Recent Short Interest

Paycor HCM GAAP EPS of -$0.01 beats by $0.06, revenue of $180.4M beats by $3.31M

Reports Q2 revenue $180.44M, consensus $177.09M. The company said, "On January 7, 2025, we announced that we had entered into a definitive agreemen...

Paycor HCM reports Q2 adjusted EPS 14c, consensus 12c

Paycor Hcm, Inc. ( ($PYCR) ) has released its Q2 earnings. Here is a breakdown of the information Paycor Hcm, Inc. presented to its investors. Payc...

Paycor Reports Growth Amid Pending Paychex Merger

In a report released today, Patrick Walravens from JMP Securities maintained a Hold rating on Paycor HCM (PYCR – Research Report). The company's sh...

Paycor HCM (PYCR) Gets a Hold from JMP Securities

William Blair analyst Jake Roberge has maintained their neutral stance on PYCR stock, giving a Hold rating today. Jake Roberge has given his Hold r...

Balanced Hold Rating on Paycor HCM Amid Strong Q2 Performance and Uncertain Outlook

Robert W. Baird analyst Mark Marcon downgraded the rating on Paycor HCM (PYCR – Research Report) to a Hold today, setting a price target of $22.50....

Hold Rating Sustained for Paycor HCM Amid Acquisition by PAYX, Reflecting Limited Upside Potential

Baird downgraded Paycor HCM (PYCR) to Neutral from Outperform with a price target of $22.50, down from $28. The firm now believes is highly unlikel...

Paycor HCM downgraded to Neutral from Outperform at Baird

Analysts fell to the sidelines weighing in on Paycor HCM (PYCR – Research Report) and Qualys (QLYS – Research Report) with neutral ratings, indicat...

Analysts Are Neutral on These Technology Stocks: Paycor HCM (PYCR), Qualys (QLYS)

Paycor Hcm, Inc. (PYCR) has disclosed a new risk, in the Regulation category. Paycor Hcm, Inc. faces significant business risk due to the restricti...

Restrictive Covenants in Merger Agreement Pose Significant Risks to Paycor's Flexibility and Growth

Invesco Main Street Small Cap Fund Q4 2024 Commentary

ACHC

ADMA

ALAB

ALSN

ATMU

BRBR

BROS

BWXT

EPRT

ESAB

ITRI

LSCC

MTSI

PAYX

PFSI

PYCR

QLYS

SGRY

TMDX

WTFC

Legal

Press Releases

Paycor HCM Shareholders are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

Paychex Enters into Definitive Agreement to Acquire Paycor

Shareholder Alert: Ademi LLP Investigates Whether Paycor HCM, Inc. Is Obtaining a Fair Price for Its Public Shareholders

Apax Funds to Sell Their Majority Stake in Paycor HCM, Inc. to Paychex, Inc.

$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Paycor HCM, Inc. - PYCR

Paycor Announces Date of Second Quarter Fiscal Year 2025 Financial Results

Advanced Human Capital Management (HCM) Solution Now Available to Convenience Retail and Wholesale Petroleum Operators as PDI Technologies Announces Entry into Embedded Partner Program with Paycor

Comments

Paycor HCM

ニュース

最新ニュース Paycor HCM (NASDAQ:PYCR) 株価情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル